Samuelsson et al. proposed that the IvIg anti-inflammatory activity is mediated by upregulation of the inhibitory Fc receptor, FcγRIIb, as IvIg has no protective effects on a mouse model of immune thrombocytopenia lacking this receptor (57). This evidence concerns the gene FCGR2B and autoimmune thrombocytopenic purpura.